Trends in the Development of MET Inhibitors for Hepatocellular Carcinoma

Future Oncology - United Kingdom
doi 10.2217/fon.16.3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Hepatology
MedicineHepatology
2019English

Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2013English

C-Met: A Potential Therapeutic Target for Hepatocellular Carcinoma

Drug discoveries & therapeutics
MedicineToxicologyPharmaceuticsPharmacology
2011English

Significance of PD‑L1 Clones and C‑MET Expression in Hepatocellular Carcinoma

Oncology Letters
Cancer ResearchOncology
2019English

Letter: Proton Pump Inhibitors and the Risk of Hepatocellular Carcinoma

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Heat Stress Induced, Ligand-Independent MET and EGFR Signaling in Hepatocellular Carcinoma.

International Journal of Hyperthermia
MedicineCancer ResearchRadiologicalPhysiologyUltrasound Technology
2017English

AIM2 Deficiency Reduces the Development of Hepatocellular Carcinoma in Mice

International Journal of Cancer
Cancer ResearchOncology
2018English

Prognostic Value of C-Met Overexpression in Hepatocellular Carcinoma: A Meta-Analysis and Review

Oncotarget
Oncology
2017English

C-Met Inhibitors

Infectious Agents and Cancer
Cancer ResearchEpidemiologyOncologyInfectious Diseases
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy